For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Peptide
Melanotan II
A cyclic α-MSH analog studied for its activity at melanocortin receptors and associated pigmentation pathways in research settings.
Quantity
$29.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
Melanotan II
1 × 10mg · $29.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.89%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 11.12mg | 99.89% |
| Jun 2026 | 11.08mg | 99.58% |
| May 2026 | 11.22mg | 99.85% |
| May 2026 | 11.30mg | 99.86% |
| Apr 2026 | 11.66mg | 99.89% |
| Feb 2026 | 12.32mg | 99.51% |
| Jan 2026 | 11.27mg | 99.82% |
Frequently researched together
Commonly studied alongside Melanotan II.
Compound information
Technical specifications
Molecular profile
| Type | Cyclic heptapeptide |
| CAS number | 121062-08-6 |
| Molecular weight | 1024.18 g/mol |
| Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Formula | C50H69N15O9 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Urology
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
1998·PMID: 9679884Wessells H, et al.
View source - Life Sciences
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
1996·PMID: 8637402Dorr RT, et al.
View source - Pharmaceutical Biotechnology
Discovery and development of novel melanogenic drugs. Melanotan-I and -II
1998·PMID: 9760697Hadley ME, Dorr RT
View source - Journal of Sexual Medicine
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
2006·PMID: 16839319Diamond LE, et al.
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.